|
US7915238B2
(en)
*
|
1999-02-01 |
2011-03-29 |
Eisai R & D Management Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
|
US20040006242A1
(en)
*
|
1999-02-01 |
2004-01-08 |
Hawkins Lynn D. |
Immunomodulatory compounds and method of use thereof
|
|
PT1147117E
(pt)
*
|
1999-02-01 |
2004-10-29 |
Eisai Co Ltd |
Compostos adjuvantes imunologicos
|
|
US6835721B2
(en)
|
1999-02-01 |
2004-12-28 |
Eisai Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
|
US7914799B2
(en)
*
|
2001-08-27 |
2011-03-29 |
Immunitor USA, Inc. |
Anti-fungal composition
|
|
JP2008530245A
(ja)
|
2005-02-18 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
尿路病原性菌株由来の抗原
|
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
DK1861120T3
(en)
|
2005-03-23 |
2016-07-25 |
Glaxosmithkline Biologicals Sa |
Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
|
|
CN101355928B
(zh)
*
|
2005-04-26 |
2013-05-22 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和方法
|
|
US20070292418A1
(en)
*
|
2005-04-26 |
2007-12-20 |
Eisai Co., Ltd. |
Compositions and methods for immunotherapy
|
|
EP2292628A3
(en)
*
|
2005-06-30 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
Compounds for preparing immunological adjuvant
|
|
KR20080080087A
(ko)
*
|
2005-09-30 |
2008-09-02 |
티티아이 엘뷰 가부시키가이샤 |
신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법
|
|
KR20080066712A
(ko)
*
|
2005-09-30 |
2008-07-16 |
티티아이 엘뷰 가부시키가이샤 |
관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
|
|
US20070078376A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Smith Gregory A |
Functionalized microneedles transdermal drug delivery systems, devices, and methods
|
|
WO2007052055A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
|
ES2377884T3
(es)
|
2005-11-04 |
2012-04-02 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
|
|
NZ594482A
(en)
|
2005-11-04 |
2012-11-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
|
|
CA2628424A1
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
|
WO2007079190A2
(en)
*
|
2005-12-29 |
2007-07-12 |
Tti Ellebeau, Inc. |
Device and method for enhancing immune response by electrical stimulation
|
|
PL2478916T3
(pl)
|
2006-01-27 |
2020-11-16 |
Seqirus UK Limited |
Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
|
|
ATE539079T1
(de)
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
|
WO2007110776A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
EP2043682B1
(en)
|
2006-07-17 |
2014-04-02 |
GlaxoSmithKline Biologicals S.A. |
Influenza vaccine
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
|
NZ575271A
(en)
|
2006-09-11 |
2011-09-30 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
|
JP2011506264A
(ja)
|
2006-12-06 |
2011-03-03 |
ノバルティス アーゲー |
インフルエンザウイルスの4つの株に由来する抗原を含むワクチン
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
CA2708148C
(en)
*
|
2007-12-18 |
2015-07-07 |
Eisai R&D Management Co., Ltd. |
Reagents and methods for the beta-keto amide synthesis of a synthetic precursor to immunological adjuvant e6020
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
US8563002B2
(en)
|
2007-12-24 |
2013-10-22 |
Glaxosmithkline Biologicals, S.A. |
Recombinant RSV antigens
|
|
JP5518041B2
(ja)
|
2008-03-18 |
2014-06-11 |
ノバルティス アーゲー |
インフルエンザウイルスワクチン抗原の調製における改良
|
|
NZ700477A
(en)
|
2009-02-17 |
2016-04-29 |
Glaxosmithkline Biolog Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
|
WO2010100632A2
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
|
EP2419129A2
(en)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Compositions for immunising against staphylococcus aerus
|
|
DE102010018462A1
(de)
|
2009-04-27 |
2011-04-07 |
Novartis Ag |
Impfstoffe zum Schutz gegen Influenza
|
|
PL2445526T3
(pl)
|
2009-06-24 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Rekombinowane antygeny rsv
|
|
SG176807A1
(en)
|
2009-06-24 |
2012-01-30 |
Id Biomedical Corp Quebec |
Vaccine
|
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
MX2012000372A
(es)
|
2009-07-06 |
2012-02-28 |
Variation Biotechnologies Inc |
Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
|
|
US10988511B2
(en)
|
2009-07-07 |
2021-04-27 |
Glaxosmithkline Biologicals Sa |
Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
|
|
EP4183412B1
(en)
|
2009-07-15 |
2024-08-14 |
GlaxoSmithKline Biologicals SA |
Rsv f protein compositions and methods for making same
|
|
CA2768343A1
(en)
|
2009-07-16 |
2011-01-20 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
|
CN102933267B
(zh)
|
2010-05-28 |
2015-05-27 |
泰特里斯在线公司 |
交互式混合异步计算机游戏基础结构
|
|
PL2575872T3
(pl)
|
2010-06-01 |
2021-02-22 |
Seqirus UK Limited |
Zatężanie antygenów szczepionkowych grypy bez liofilizacji
|
|
CA2801151A1
(en)
|
2010-06-01 |
2011-12-08 |
Novartis Ag |
Concentration of vaccine antigens with lyophilization
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
|
CA2808965C
(en)
|
2010-08-20 |
2020-01-07 |
Theraject, Inc. |
Soluble needle arrays for delivery of influenza vaccines
|
|
SG190937A1
(en)
|
2010-12-14 |
2013-07-31 |
Glaxosmithkline Biolog Sa |
Mycobacterium antigenic composition
|
|
US10736844B2
(en)
|
2011-01-13 |
2020-08-11 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
|
ES3018416T3
(es)
|
2011-01-26 |
2025-05-16 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
|
BR112013031028A2
(pt)
|
2011-06-03 |
2016-11-29 |
3M Innovative Properties Co |
conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
|
|
EP3153180A1
(en)
*
|
2011-06-03 |
2017-04-12 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
诺华股份有限公司 |
酪氨酸连接方法
|
|
RU2636350C2
(ru)
|
2011-11-07 |
2017-11-22 |
Новартис Аг |
МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
|
|
CA2894442C
(en)
|
2012-01-12 |
2020-01-21 |
Variation Biotechnologies Inc. |
Compositions and methods for treating viral infections
|
|
EP4008354A1
(en)
|
2012-01-27 |
2022-06-08 |
Variation Biotechnologies Inc. |
Methods and compositions for therapeutic agents
|
|
EP2822584A1
(en)
|
2012-03-08 |
2015-01-14 |
Novartis AG |
Combination vaccines with tlr4 agonists
|
|
CA2866406A1
(en)
|
2012-03-08 |
2013-09-12 |
Novartis Ag |
Adjuvanted formulations of booster vaccines
|
|
CN104203270A
(zh)
|
2012-03-18 |
2014-12-10 |
葛兰素史密丝克莱恩生物有限公司 |
针对人乳头状瘤病毒的接种方法
|
|
SG11201500573RA
(en)
|
2012-08-06 |
2015-02-27 |
Glaxosmithkline Biolog Sa |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
BR112015005056A2
(pt)
|
2012-09-06 |
2017-11-21 |
Novartis Ag |
vacinas de combinação com sorogrupo b meningococcus e d/t/p
|
|
MX2015004171A
(es)
|
2012-10-02 |
2015-10-22 |
Glaxosmithkline Biolog Sa |
Conjugados de sacaridos no lineales.
|
|
EP2906239A1
(en)
|
2012-10-12 |
2015-08-19 |
GlaxoSmithKline Biologicals SA |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
|
CN105142666A
(zh)
|
2012-11-30 |
2015-12-09 |
葛兰素史密丝克莱恩生物有限公司 |
假单胞菌抗原和抗原组合
|
|
US9827190B2
(en)
|
2013-02-01 |
2017-11-28 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
|
|
EP4421177A3
(en)
|
2013-03-13 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Prefusion rsv f proteins and their use
|
|
US10058603B2
(en)
|
2013-03-15 |
2018-08-28 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
SG11201600709TA
(en)
|
2013-08-05 |
2016-02-26 |
Glaxosmithkline Biolog Sa |
Combination immunogenic compositions
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
MX377794B
(es)
|
2014-03-26 |
2025-03-10 |
Glaxosmithkline Biologicals Sa |
Antigenos estafilococicos mutantes.
|
|
EP3154576A1
(en)
|
2014-06-13 |
2017-04-19 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic combinations
|
|
WO2016140702A1
(en)
|
2015-03-03 |
2016-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces |
Display platform from bacterial spore coat proteins
|
|
US10065978B2
(en)
|
2015-11-24 |
2018-09-04 |
University Of South Carolina |
Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
CA3045952A1
(en)
|
2016-12-07 |
2018-06-14 |
Glaxosmithkline Biologicals Sa |
Novel process
|
|
WO2018109220A2
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
US10682359B2
(en)
|
2017-03-31 |
2020-06-16 |
University Of South Carolina |
Inhibitors of glucose kinases, along with methods of their formation and use
|
|
EP3612562A2
(en)
|
2017-04-19 |
2020-02-26 |
Institute for Research in Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
|
US20210187098A1
(en)
|
2017-04-28 |
2021-06-24 |
Glaxosmithkline Biologicals Sa |
Vaccination
|
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
WO2020010016A1
(en)
|
2018-07-04 |
2020-01-09 |
Sutrovax, Inc. |
Self-adjuvanted immunogenic conjugates
|
|
US11059842B2
(en)
|
2019-04-29 |
2021-07-13 |
University Of South Carolina |
Monosaccharide amine and 3-nitro-2-phenyl-2H-chromene based inhibitors of glucose kinases
|
|
US11555047B2
(en)
|
2019-10-31 |
2023-01-17 |
University Of South Carolina |
One-step synthesis of phosphate-based inhibitors and applications thereof
|
|
WO2021245025A1
(en)
|
2020-06-01 |
2021-12-09 |
Loop Diagnostics, S.L. |
Method and kit for the early detection of sepsis
|
|
JP2023553854A
(ja)
|
2020-12-02 |
2023-12-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ドナー鎖補完性fimh
|